Healthy Volunteers Clinical Trial
Official title:
Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) to Healthy Volunteers Compared to Erbitux
Background Colorectal cancer (CRC) is one of the most common human malignant tumors. The
incidence and mortality of colorectal cancer in our country are on the rise. Surgery-based,
combined with chemotherapy, radiotherapy comprehensive treatment, is the main treatment of
colorectal cancer. Surgical resection has been recognized as the primary treatment of
colorectal cancer. However, due to the majority of patients already advanced at the time of
diagnosis, some difficulties are brought to radical surgery. Therefore, the importance of
chemotherapy for colorectal cancer gradually been clinically recognized, But rarely survive
more than 18 months." In addition to chemotherapy, there is now a more ideal model of cancer
treatment- molecular targeted therapies, including monoclonal antibody drugs such as
cetuximab, as well as small molecule tyrosine kinases Inhibitors gefitinib and so on.
Molecular targeted drugs make use of the difference in molecular biology between tumor cells
and normal cells. Targeting drugs to tumor cells and inhibiting the growth and proliferation
of the cells can achieve the therapeutic effect, which has the advantages of high specificity
and low adverse reaction. The bio-targeted drug cetuximab is the first drug approved to
marketed as an epidermal growth factor receptor (EGFR)-targeting immunoglobulin
1（IgG1）monoclonal antibody. Cetuximab, either monotherapy or combined radiotherapy and
chemotherapy, can exert excellent anti-tumor activity in EGFR-positive malignant tumors and
can significantly enhance the efficacy of radiotherapy and chemotherapy.
Reference to cetuximab injection, guilin sanjin Co., Ltd. and dragonboat Co., Ltd. jointly
developed a recombinant anti-EGFR human mouse chimeric monoclonal antibody (R & D code:
CDP1).The primary structure of CDP1 is exactly the same with cetuximab, the higher structure
and Physical and chemical properties and cetuximab are highly similar. Pharmacodynamic
activity in vivo and in vitro, pharmacokinetic characteristics and toxicological reactions
are also similar to cetuximab. CDP1 selected with cetuximab consistent formulations,
prescriptions, specifications.
CDP1 was approved by China Food and Drug Administration (No. 2016L06884) in August 2016 for
clinical studies. According to the contents of the document and guidelines for biological
analogs, the clinical pharmacokinetic and clinical effectiveness comparison tests of CDP1 and
the safety and immunogenicity assessment are planned.
OBJECTIVES:
Primary:
To compare the pharmacokinetic characteristics of a single dose between CDP1 and the original
drug Erbitux in healthy volunteers.
Secondary :
To compare the safety and immunogenic characteristics of the single dose between CDP1 and the
original drug Erbitux in healthy volunteers.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |